samedan logo
 
 
 
spacer
home > ebr > spring 2018 > beyond the genome
PUBLICATIONS
European Biopharmaceutical Review

Beyond the Genome

The epigenome may hold the key to precision medicine, revealing critically important chemical modifications within DNA that alter the structure, function, and regulation of genes. This exciting and rapidly evolving area brings new perspectives to fundamental biological processes underpinning human disease, development, and ageing. Targeting of precise and powerful epigenetic mechanisms may advance personalised medicine beyond the realms of genomics, bringing opportunities for novel therapeutics and diagnostics that will improve patient outcomes and make efficient use of healthcare resources.

Epigenetic modifications within genomes do not alter the underlying sequence of DNA. Instead, precise chemical changes to DNA or RNA nucleotides and histone proteins alter the regulation and function of genes. Epigenetic modifications are inheritable and can be added or removed in response to specific external factors. Patientís lifestyles (such as smoking and diet), environment, and the stressors that people are exposed to influence the dynamic structure and function of epigenomes, impacting the delicate balance of chemical modifications that are essential to numerous cellular processes.

Informative Diagnostics

Dysregulation of epigenetic pathways can have disastrous consequences; mutations within epigenetic regulators are among the most prevalent across all cancers (1). In addition to cancers, changes within the epigenome are associated with development of a wide range of diseases and health conditions, including neurological and metabolic diseases (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jason Mellad is the CEO at Cambridge Epigenetix, which aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of 5hmC epigenetic modification. Jason has a BSc in molecular biology and chemistry from Tulane University, US, and was a Marshall Scholar at the University of Cambridge, UK, where he completed a PhD in medicine.
spacer
Dr Jason Mellad
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takedaís Hematology Portfolio and Pipeline
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement